{"id":80,"date":"2014-08-27T11:12:02","date_gmt":"2014-08-27T11:12:02","guid":{"rendered":"http:\/\/delveinsightblog.wordpress.com\/?p=80"},"modified":"2025-05-02T16:28:02","modified_gmt":"2025-05-02T10:58:02","slug":"infectious-disease-and-vaccines-pipeline-reports","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/infectious-disease-and-vaccines-pipeline-reports","title":{"rendered":"Infectious Disease and Vaccines Pipeline Reports"},"content":{"rendered":"<p><img decoding=\"async\" class=\"aligncenter wp-image-11297 size-full\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2014\/08\/01210237\/berries.png\" alt=\"berries\" width=\"600\" height=\"265\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2014\/08\/01210237\/berries.png 600w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2014\/08\/01210237\/berries-300x133.png 300w\" sizes=\"(max-width: 600px) 100vw, 600px\" \/><\/p>\n<blockquote>\n<p style=\"text-align: center; padding-left: 30px;\"><span style=\"text-decoration: underline;\"><span style=\"color: #993366; text-decoration: underline;\"><strong>DelveInsight is helping worldwide Pharmaceutical companies with its Market Intelligence Reports.<\/strong><\/span><\/span><\/p>\n<p style=\"text-align: center; padding-left: 30px;\"><strong><span style=\"text-decoration: underline;\"><span style=\"color: #3366ff; text-decoration: underline;\"><a style=\"color: #3366ff; text-decoration: underline;\" href=\"http:\/\/clt.bmetrack.com\/c\/l?u=3C1CEBC&amp;e=50AFB8&amp;c=682C3&amp;t=0&amp;email=CUNgYCAHHSEvZ5VfTCDtzzbYKbicPu0Y\" target=\"_blank\" rel=\"noopener noreferrer\">VISIT OUR WEBSITE<\/a><\/span><\/span><\/strong><\/p>\n<\/blockquote>\n<p><strong>Infectious Diseases and Vaccines<\/strong><span class=\"Apple-converted-space\"><br \/>\n<\/span><\/p>\n<p>The infectious disease (ID) vaccine pipeline is rich and robust. However, indications such as HIV, Tuberculosis and HCV have high demand for the development of a first vaccine, and even routine vaccinations, such as those for influenza can be improved in terms of safety and efficacy. Such unmet needs are driving the continued development of ID vaccines. <em><span class=\"Apple-converted-space\"><br \/>\n<\/span><\/em><\/p>\n<p><strong>Get\u00a0 Notified About Whats in Others Pipeline<span class=\"Apple-converted-space\"><br \/>\n<\/span><\/strong><\/p>\n<p>The research work for curing Infectious disease has rapidly assumed a prioritized role within the overall scientific portfolio. The number of vaccines development underway has increased substantially for the HCV, HIV, Tuberculosis and Influenza infections.<\/p>\n<p>Get notified about all the under development vaccines worldwide and the technology they are using, stage of development, their targets, mechanism of action with our Pipeline reports. The best strategic report that will not even give you the overall developing drug profiles but also therapeutic assessment and comparative analysis at every step such as monotherapy, combination, route of administration. <em><span class=\"Apple-converted-space\"><br \/>\n<\/span><\/em><\/p>\n<p><strong>Pipeline Insights Reports<\/strong><span class=\"Apple-converted-space\"><br \/>\n<\/span><\/p>\n<p>HCV Vaccine-Pipeline Insights, 2014<span class=\"Apple-converted-space\">\u00a0<\/span><\/p>\n<p>HIV Vaccine-Pipeline Insights, 2014<span class=\"Apple-converted-space\">\u00a0<\/span><\/p>\n<p>Influenza Vaccine-Pipeline Insights, 2014<span class=\"Apple-converted-space\">\u00a0<\/span><\/p>\n<p>Tuberculosis Vaccine-Pipeline Insights, 2014<span class=\"Apple-converted-space\"><br \/>\n<\/span><\/p>\n<p><strong><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"mailto:info@delveinsight.com\" target=\"_blank\" rel=\"noopener noreferrer\">ASK FOR SAMPLE PAGES NOW<\/a><\/span><\/strong><\/p>\n<p><span style=\"color: #ff0000;\">For further information email us at info@delveinsight.com<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight is helping worldwide Pharmaceutical companies with its Market Intelligence Reports. VISIT OUR WEBSITE Infectious Diseases and Vaccines The infectious disease (ID) vaccine pipeline is rich and robust. However, indications such as HIV, Tuberculosis and HCV have high demand for the development of a first vaccine, and even routine vaccinations, such as those for influenza [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[119,204,211,213,216,246,290,297,319,322,326,327,328,17232,381,391,407,465,466,469,472,473,476,485,508,512,566,569,579,585,596],"industry":[17225],"therapeutic_areas":[17231],"class_list":["post-80","post","type-post","status-publish","format-standard","hentry","category-articles","tag-biotech","tag-delveinsight","tag-development","tag-discovery","tag-drug","tag-filed","tag-hepatitis-c-virus","tag-hiv","tag-ind-filed","tag-indication","tag-infectious-disease","tag-infectious-diseases","tag-infectious-diseases-and-vaccines","tag-influenza-infections","tag-market-research","tag-mechanism-of-action","tag-monotherapy","tag-pharma-companies","tag-pharma-company","tag-pharmaceutical-companies","tag-phase-i","tag-phase-ii","tag-phase-iii-pipeline","tag-pipeline-reports","tag-report-buyers","tag-reports","tag-therapeutic-area","tag-therapeutics","tag-track-your-closest-competitors","tag-tuberculosis","tag-vaccine","industry-pharmaceutical","therapeutic_areas-infectious-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Infectious Disease and Vaccines Pipeline Reports - DelveInsight<\/title>\n<meta name=\"description\" content=\"The infectious disease (ID) vaccine pipeline is rich and robust. However, indications such as HIV, Tuberculosis and HCV have high demand for the...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/infectious-disease-and-vaccines-pipeline-reports\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Infectious Disease and Vaccines Pipeline Reports - DelveInsight\" \/>\n<meta property=\"og:description\" content=\"The infectious disease (ID) vaccine pipeline is rich and robust. However, indications such as HIV, Tuberculosis and HCV have high demand for the...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/infectious-disease-and-vaccines-pipeline-reports\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-08-27T11:12:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-02T10:58:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2014\/08\/berries.png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Infectious Disease and Vaccines Pipeline Reports - DelveInsight","description":"The infectious disease (ID) vaccine pipeline is rich and robust. However, indications such as HIV, Tuberculosis and HCV have high demand for the...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/infectious-disease-and-vaccines-pipeline-reports","og_locale":"en_US","og_type":"article","og_title":"Infectious Disease and Vaccines Pipeline Reports - DelveInsight","og_description":"The infectious disease (ID) vaccine pipeline is rich and robust. However, indications such as HIV, Tuberculosis and HCV have high demand for the...","og_url":"https:\/\/www.delveinsight.com\/blog\/infectious-disease-and-vaccines-pipeline-reports","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2014-08-27T11:12:02+00:00","article_modified_time":"2025-05-02T10:58:02+00:00","og_image":[{"url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2014\/08\/berries.png","type":"","width":"","height":""}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/infectious-disease-and-vaccines-pipeline-reports","url":"https:\/\/www.delveinsight.com\/blog\/infectious-disease-and-vaccines-pipeline-reports","name":"Infectious Disease and Vaccines Pipeline Reports - DelveInsight","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/infectious-disease-and-vaccines-pipeline-reports#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/infectious-disease-and-vaccines-pipeline-reports#primaryimage"},"thumbnailUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2014\/08\/berries.png","datePublished":"2014-08-27T11:12:02+00:00","dateModified":"2025-05-02T10:58:02+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"The infectious disease (ID) vaccine pipeline is rich and robust. However, indications such as HIV, Tuberculosis and HCV have high demand for the...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/infectious-disease-and-vaccines-pipeline-reports"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/infectious-disease-and-vaccines-pipeline-reports#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2014\/08\/01210237\/berries.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2014\/08\/01210237\/berries.png","width":600,"height":265,"caption":"berries"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":null,"coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Biotech<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">development<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Discovery<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Drug<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Filed<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Hepatitis C Virus<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">HIV<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">IND filed<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Indication<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Infectious Disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Infectious Diseases<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Infectious Diseases and Vaccines<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Influenza infections<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Market Research<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Mechanism of Action<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">monotherapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Pharma Companies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Pharma Company<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Pharmaceutical companies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Phase I<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Phase II<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Phase III Pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Pipeline Reports<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Report Buyers<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Reports<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">therapeutic Area<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Track your closest Competitors<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Tuberculosis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Vaccine<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Biotech<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">development<\/span>","<span class=\"advgb-post-tax-term\">Discovery<\/span>","<span class=\"advgb-post-tax-term\">Drug<\/span>","<span class=\"advgb-post-tax-term\">Filed<\/span>","<span class=\"advgb-post-tax-term\">Hepatitis C Virus<\/span>","<span class=\"advgb-post-tax-term\">HIV<\/span>","<span class=\"advgb-post-tax-term\">IND filed<\/span>","<span class=\"advgb-post-tax-term\">Indication<\/span>","<span class=\"advgb-post-tax-term\">Infectious Disease<\/span>","<span class=\"advgb-post-tax-term\">Infectious Diseases<\/span>","<span class=\"advgb-post-tax-term\">Infectious Diseases and Vaccines<\/span>","<span class=\"advgb-post-tax-term\">Influenza infections<\/span>","<span class=\"advgb-post-tax-term\">Market Research<\/span>","<span class=\"advgb-post-tax-term\">Mechanism of Action<\/span>","<span class=\"advgb-post-tax-term\">monotherapy<\/span>","<span class=\"advgb-post-tax-term\">Pharma Companies<\/span>","<span class=\"advgb-post-tax-term\">Pharma Company<\/span>","<span class=\"advgb-post-tax-term\">Pharmaceutical companies<\/span>","<span class=\"advgb-post-tax-term\">Phase I<\/span>","<span class=\"advgb-post-tax-term\">Phase II<\/span>","<span class=\"advgb-post-tax-term\">Phase III Pipeline<\/span>","<span class=\"advgb-post-tax-term\">Pipeline Reports<\/span>","<span class=\"advgb-post-tax-term\">Report Buyers<\/span>","<span class=\"advgb-post-tax-term\">Reports<\/span>","<span class=\"advgb-post-tax-term\">therapeutic Area<\/span>","<span class=\"advgb-post-tax-term\">therapeutics<\/span>","<span class=\"advgb-post-tax-term\">Track your closest Competitors<\/span>","<span class=\"advgb-post-tax-term\">Tuberculosis<\/span>","<span class=\"advgb-post-tax-term\">Vaccine<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 12 years ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on Aug 27, 2014","modified":"Updated on May 2, 2025"},"absolute_dates_time":{"created":"Posted on Aug 27, 2014 11:12 am","modified":"Updated on May 2, 2025 4:28 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/80","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=80"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/80\/revisions"}],"predecessor-version":[{"id":31600,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/80\/revisions\/31600"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=80"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=80"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=80"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=80"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=80"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}